Huons Global Valuation
Is A084110 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A084110 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A084110 (₩36800) is trading below our estimate of fair value (₩71595.35)
Significantly Below Fair Value: A084110 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A084110?
Other financial metrics that can be useful for relative valuation.
| What is A084110's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | ₩449.48b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.1x |
| Enterprise Value/EBITDA | 5.8x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does A084110's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 34x | ||
A243070 Huons | 8.3x | 15.3% | ₩332.3b |
A041960 Komipharm International | 87.2x | n/a | ₩299.5b |
A001060 JW Pharmaceutical | 19.2x | 29.4% | ₩675.1b |
A003220 Daewon Pharmaceutical | 21.2x | 35.6% | ₩310.8b |
A084110 Huons Global | 10x | n/a | ₩449.5b |
Price-To-Earnings vs Peers: A084110 is good value based on its Price-To-Earnings Ratio (10x) compared to the peer average (34x).
Price to Earnings Ratio vs Industry
How does A084110's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?
Price-To-Earnings vs Industry: A084110 is good value based on its Price-To-Earnings Ratio (10x) compared to the KR Pharmaceuticals industry average (14.7x).
Price to Earnings Ratio vs Fair Ratio
What is A084110's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 10x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A084110's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.